Mdxhealth is a commercial-stage precision diagnostics company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of prostate cancer and other urologic diseases. The Company’s tests are based on proprietary genetic, epigenetic and other complex molecular technologies.

Mdxhealth is dedicated to providing highly accurate and clinically actionable urologic solutions to inform patient diagnosis and treatment while improving healthcare economics for payers and providers.


Michael K. McGarrity

Chief Executive Officer, Director

Ron Kalfus

Chief Financial Officer

John Bellano

Chief Commercial Officer

Joseph Sollee

Executive Vice President of Corporate Development and General Counsel 

Miriam Reyes

Executive Vice President of Operations

Jason Poole Ph.D.

Chief Scientific Officer


Board of Directors

Koen Hoffman

Chairman and Independent Director, representing Ahok BV

Eric Bednarski, Ph.D.


Don Hardison
Independent Director
Michael K. McGarrity

Chief Executive Officer, Director

Regine Slagmulder

Independent Director, representing Regine Slagmulder BV

Sanford J. Siegel, M.D.
Independent Director
Hilde Windels

Independent Director, representing Hilde Windels BVBA

Licensure & Accreditations

Mdxhealth endeavors to meet and exceed industry standards for clinical laboratory testing.

Clinical Research Network

Mdxhealth collaborates with a large number of international academic institutes, medical centers and organizations: